Tubize-Fin (BR:TUB) — Market Cap & Net Worth
Market Cap & Net Worth: Tubize-Fin (TUB)
Tubize-Fin (BR:TUB) has a market capitalization of $9.89 Billion (€8.46 Billion) as of May 2, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #2256 globally and #8 in its home market, demonstrating a -6.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tubize-Fin's stock price €195.70 by its total outstanding shares 44512598 (44.51 Million). Analyse TUB cash flow metrics to see how efficiently the company converts income to cash.
Tubize-Fin Market Cap History: 2015 to 2026
Tubize-Fin's market capitalization history from 2015 to 2026. Data shows growth from $3.34 Billion to $10.18 Billion (12.76% CAGR).
Index Memberships
Tubize-Fin is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL All Share
BSPT
|
$806.02 Billion | 1.23% | #14 of 108 |
Weight: Tubize-Fin's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tubize-Fin Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tubize-Fin's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
558201.29x
Tubize-Fin's market cap is 558201.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
82.13x
Tubize-Fin's market cap is 82.13 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.93 Billion | $302.00K | $181.19 Million | 9711.85x | 16.19x |
| 2017 | $3.18 Billion | $272.23 Million | $285.93 Million | 11.66x | 11.11x |
| 2018 | $3.04 Billion | $288.25 Million | $285.16 Million | 10.53x | 10.65x |
| 2019 | $3.20 Billion | $3.00K | $283.70 Million | 1065652.36x | 11.27x |
| 2022 | $3.63 Billion | $8.15K | $85.17 Million | 445300.95x | 42.62x |
| 2024 | $7.40 Billion | $13.26K | $90.10 Million | 558201.29x | 82.13x |
Competitor Companies of TUB by Market Capitalization
Companies near Tubize-Fin in the global market cap rankings as of May 2, 2026.
Key companies related to Tubize-Fin by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Tubize-Fin Historical Marketcap From 2015 to 2026
Between 2015 and today, Tubize-Fin's market cap moved from $3.34 Billion to $ 10.18 Billion, with a yearly change of 12.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €10.18 Billion | -6.36% |
| 2025 | €10.88 Billion | +46.98% |
| 2024 | €7.40 Billion | +99.73% |
| 2023 | €3.70 Billion | +2.08% |
| 2022 | €3.63 Billion | -21.14% |
| 2021 | €4.60 Billion | +9.96% |
| 2020 | €4.19 Billion | +30.93% |
| 2019 | €3.20 Billion | +5.29% |
| 2018 | €3.04 Billion | -4.38% |
| 2017 | €3.18 Billion | +8.27% |
| 2016 | €2.93 Billion | -12.21% |
| 2015 | €3.34 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Tubize-Fin was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.89 Billion USD |
| MoneyControl | $9.89 Billion USD |
| MarketWatch | $9.89 Billion USD |
| marketcap.company | $9.89 Billion USD |
| Reuters | $9.89 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tubize-Fin
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. It engages in discovering and developing treatments for patients suffering from serious illnesses that affect the immune system or the central nervous system. The company was incorporated in 1928 and is based in Brussels, Belgium.